Neogen Corporation NEOG

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
55/100
Moderate

About Neogen Corporation

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural … Full NEOG analysis →

Competitive advantage assessment

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.78). Low volatility confirms durable consumable pricing.
  • Above-Peer Asset Productivity Asset productivity is strong vs peers (score 0.70). Above-peer ROA underpins the growth durability narrative.

Key risks

  • Operating Margin Compression Operating margin trend is negative (score 0.16). Sustained compression would reduce the commercial moat.
  • Elevated Leverage Leverage is elevated vs peers (score 0.34). High net debt/EBITDA limits the balance sheet's acquisition firepower.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
61

Where NEOG ranks in Diagnostics & Research

Neogen Corporation ranks #23 of 62 scored companies in Diagnostics & Research by moat score — the top 37%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

Moat scores for companies ranked near NEOG in Diagnostics & Research
# Company Moat score Rating
19 Burning Rock Biotech Limited BNR 60/100 Moderate
20 Fonar Corporation FONR 59/100 Moderate
21 GeneDx Holdings Corp. WGSWW 58/100 Moderate
22 Labcorp Holdings Inc. LH 57/100 Moderate
23 Neogen Corporation NEOG 55/100 Moderate
24 ICON plc ICLR 54/100 Moderate
25 RadNet, Inc. RDNT 54/100 Moderate
26 Charles River Laboratories Inte CRL 54/100 Moderate
27 Natera, Inc. NTRA 54/100 Moderate

See every Medical Devices & Diagnostics company ranked by moat score →

How NEOG scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 61 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 56 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 59 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 44 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 50 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 47 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding NEOG's moat

What is Neogen Corporation's moat score?

Neogen Corporation (NEOG) scores 54 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #23 of 62 scored companies in Diagnostics & Research, the top 37%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (61/100) and its weakest is Commercial Execution (44/100).

How does Neogen Corporation compare with other Diagnostics & Research companies?

Neogen Corporation ranks #23 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Labcorp Holdings Inc. (LH) at 56 just above it and ICON plc (ICLR) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is Neogen Corporation scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Neogen Corporation?

The Medical Devices & Diagnostics template measures 6 defenses, and NEOG scores: Pricing Power & Consumable Moat (61), R&D Pipeline & Capital Returns (56), FCF Quality & Cash Conversion (59), Commercial Execution (44), Capital Structure & Resilience (50), Growth Durability (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000